A tiny mouse has a heart that beats 5-14 times per second, in contrast to the human heart at once per second. And yet mice, and scores of other animals are used extensively in cardiovascular research, despite the fact they do not experience heart attacks and strokes as humans do.
A tiny mouse has a heart that beats 5-14 times per second, in
contrast to the human heart at once per second. And yet mice, and
scores of other animals are used extensively in cardiovascular
research, despite the fact they do not experience heart attacks and
strokes as humans do.
In attempts to simulate human cardiac disorders, researchers carry
out painful procedures on mice and rats, such as inserting a clamp
into the aorta to force the heart to work harder. This causes
increased muscle mass and eventual heart attack due to vascular
constriction.
This artificial state differ significantly from the progressive
development of human cardiovascular disease that arises from
multiple lifestyle and genetic factors, delaying progress in
treatments for human cardiovascular disease, while causing immense
animal suffering.
Better and human relevant methods are available to replace animals.
Heart-on-a-chips have been around for over a decade, composed of
human heart cells to model cardiac function. Now, a team of
scientists has created a systematic approach to developing the
chips, that will lead to greater standardization. Other research is
using human heart tissue obtained from surgeries to study heart
disease, deriving new findings for treating heart failure,
atherosclerosis and strokes.
Heart-on-a-chip: A microfluidic marvel shaping the future of
cardiovascular research
In an effort to replace animal testing and improve the success rate
of vital heart treatments, scientists at the National Institute of
Standards and Technology (NIST) have developed a tool that will help
construct heart-on-a-chip devices.
A heart-on-a-chip is a small intricate device designed to replicate
a human heart. Derived from human stem cells and with microchannels
that effectively mimic blood vessels, it allows researchers to
safely test drugs and observe their efficacy far more accurately and
without the harm caused when testing on animals. This major step
forward in drug development addresses the limitations of current
methods and has even greater potential; while this specific chip is
focused on the heart, the same technology can also be used to create
chips that replicate other organs too.
The goal, says NIST researcher Dr. Darwin Reyes, is to “be able to
skip the animal testing altogether. This would also shorten the time
it takes to test drugs, hopefully making the medications cost less.”
Living heart muscle slices drive RNA research into heart
failure
Researchers at Hannover Medical School (MHH) in Germany have derived
new insights into heart disease and potential treatments without
experimenting on animals. In a novel study led by Professor Thomas
Thum, MD, PhD, the researchers obtained diseased human hearts that
were removed during transplant, and cultured them in the laboratory
to form living myocardial slices (LMS). They then added a blocker to
the tissue slices to see the effects of switching off the harmful
function of a noncoding RNA snippet called miR-21, which plays a
role in cardiac fibrosis, or stiffening of the heart muscle. The
remarkable result was that the heart tissue began to heal; the
diseased portion became more elastic as the heart muscle cells
relaxed and began to beat with increased viability.
Commenting on the study, Professor Thum said: "To our knowledge,
this is the first study in which the effects of miR-21 have been
investigated directly on living human heart tissue. The LMS model
has proven its worth in providing preclinical proof of efficacy and
should also contribute to a significant reduction in animal testing
in the future. The tests in the cultivation chambers have shown that
the miR-21 blocker is a potential drug candidate for stopping and
even reversing fibrosis development in heart failure."
In our cellular 'glue,' scientists find answers about heart attacks,
strokes, more
Getty - Heart Attack Stock photo
Scientists at the University of Virginia conducted animal-free
research that may lead to better treatments for cardiovascular
disease - the leading cause of death worldwide. The researchers set
out to learn more about the atherosclerotic plaques that lead to
strokes and heart attacks by studying extracellular matrix, a
glue-like material secreted by human blood vessels.
Extracting smooth muscle cells from 123 heart transplant donors,
they analyzed the protein composition, and were able to identify 20
locations on human chromosomes that contain genes that are connected
to the production of these proteins. They also found gene variations
that put people at a greater risk of heart condition. The findings
shed light on important knowledge that will be beneficial during the
development of new drugs and treatments.